What Foundayo Means for Employer Health Plans

Employers have spent the last several years navigating rising healthcare costs, and obesity treatments are quickly becoming one of the next major decisions shaping benefit strategy, pharmacy spend, and workforce wellbeing.The Food and Drug Administration (FDA) recently approved Foundayo™, a once-daily oral medication for obesity management developed by Eli Lilly. As reported by NPR, Foundayo is only the second GLP-1 pill approved in the United States, introducing a new option for individuals seeking obesity treatment without injections. 

While the approval itself is noteworthy, the bigger question for employers is this: 

What could wider access to oral GLP-1 medications mean for healthcare costs, employee demand, and long-term benefits strategy? 

Key Takeaway for Employers 

Foundayo's approval could increase employee interest in obesity treatment by offering a convenient oral alternative to injectable GLP-1 medications. Employers should evaluate how expanding treatment options may affect pharmacy spending, workforce health outcomes, benefits strategy, and long-term healthcare costs. 

What Is Foundayo? 

Foundayo is a once-daily oral GLP-1 medication approved for obesity treatment. 

Like other GLP-1 therapies, it works by mimicking a natural hormone that helps regulate appetite and food intake. Patients often feel fuller sooner, which can support meaningful weight loss when combined with lifestyle modifications. 

Unlike many injectable obesity medications currently on the market, Foundayo is taken as a pill and does not require injections. 

Another notable distinction is that Foundayo uses a small-molecule ingredient called orforglipron rather than a peptide-based formulation. According to Eli Lilly's official press release, this allows the medication to be taken without fasting requirements, food restrictions, or specific timing instructions, unlike the oral form of Wegovy, which requires patients to fast before use. 

For employees who may be hesitant to use injectable medications, this convenience could make treatment more appealing. 

Why Employers Should Pay Attention 

Historically, obesity medications have often been viewed through a pharmacy cost lens. 

Today, many employers are evaluating obesity treatment as part of a broader workforce health strategy. 

Obesity is associated with numerous chronic conditions, including diabetes, cardiovascular disease, musculoskeletal disorders, and other health concerns that can impact healthcare utilization, productivity, absenteeism, and employee wellbeing. According to the GLP-1 Drugs: Employer Coverage Decision Guide, obesity affects more than 40% of U.S. adults and contributes to $173 billion in annual healthcare spending, making treatment access a growing strategic priority for plan sponsors. 

As treatment options continue to expand, employers may see increased employee interest in GLP-1 therapies. 

• Key questions employers should consider include: 
• Will oral options increase employee demand for obesity treatment? 
• How could increased utilization affect pharmacy spending? 
• What impact might obesity treatment have on workforce health outcomes? 
• How should obesity medications fit into broader healthcare and total wellbeing strategies? 
• What role should obesity management play within long-term cost-containment efforts? 

These questions are becoming increasingly important as obesity treatment becomes more accessible. 

How Oral GLP-1s Could Impact Healthcare Costs 

The introduction of oral GLP-1 medications may represent more than just another drug launch. 

For some employers, it could signal a shift in utilization patterns. 

Convenience often influences healthcare adoption. Employees who previously avoided injectable treatments may be more willing to pursue obesity management through an oral medication. As CNBC noted at the time of approval, Foundayo is designed to expand reach among patients who had not yet tried a weight-loss drug, a population that could be significant within employer health plans. 

While increased utilization could improve access to care and potentially support better long-term health outcomes, it could also increase short-term pharmacy spending. 

GLP-1s already account for 17% of total pharmacy spend, up from just 9% in 2022, and oral options may accelerate that trend further. 

This creates a balancing act for employers attempting to manage rising healthcare costs while supporting employee health and wellbeing. 

Organizations that proactively evaluate utilization trends, plan design strategies, and pharmacy management approaches may be better positioned to navigate future cost pressures. 

Clinical Results Continue to Drive Interest 

Clinical trial data suggests that Foundayo may offer meaningful weight-loss results. 

As reported by NPR and confirmed in Eli Lilly's clinical data, participants taking the highest dose of Foundayo for 72 weeks lost an average of 27.3 pounds, or 12.4% of body weight, compared with 2.2 pounds among participants receiving a placebo. The FDA granted the approval in just 50 days, the fastest for a new molecular entity since 2002. 

The most reported side effects were gastrointestinal and included nausea, constipation, and diarrhea, consistent with the broader GLP-1 drug class. 

While some injectable medications may demonstrate greater weight-loss outcomes, oral treatment options may appeal to employees seeking a more convenient approach. 

Cost and Coverage Considerations 

For many employers, the biggest question is not whether GLP-1 medications work. 

The bigger question is whether coverage is sustainable. 

Coverage for obesity medications varies significantly across employer-sponsored health plans. Even as additional treatment options become available, affordability and plan design considerations remain key factors influencing adoption. It's also worth noting that new direct-to-consumer GLP-1 pricing trends and government pricing agreements may further complicate how employees perceive plan coverage, making clear communication and clinical guardrails more important than ever. 

On pricing, NPR reported that the starting cash-pay price for Foundayo is $149 per month, with commercial copays potentially as low as $25 per month with a Lilly savings card, and Medicare coverage projected to begin in July 2026 at $50 per month. While lower entry pricing may broaden access, employers should be careful not to conflate consumer-facing prices with plan-level cost exposure. 

Employers evaluating obesity coverage strategies should consider: 

• Pharmacy spend implications 
• Clinical outcomes 
• Workforce health objectives 
• Employee experience 
• Long-term healthcare costs 
• Population health goals 

As additional GLP-1 options enter the market, employers may have more flexibility in designing strategies that balance cost and access. For a deeper look at the 2026 pharmacy benefits landscape, including GLP-1 strategy, PBM reform, and biosimilar trends, download OneDigital's 2026 Leading Trends in Pharmacy Benefits Management guide. 

Workforce Health Implications 

The approval of Foundayo reflects a broader shift occurring across healthcare and workforce wellbeing. 

Employers are increasingly looking beyond traditional disease management approaches and evaluating how health investments contribute to employee outcomes, engagement, and productivity. A modern population health management strategy, one that connects claims data to action, is essential for tying obesity treatment decisions to chronic condition prevention and long-term plan sustainability. 

As obesity treatment evolves, organizations may need to rethink how benefits strategies support long-term workforce health. 

The conversation is no longer simply about weight management. 

It is increasingly about chronic condition prevention, healthcare affordability, employee experience, and organizational performance. 

What Employers Should Do Next 

The approval of Foundayo is likely to accelerate conversations around obesity treatment, healthcare affordability, workforce wellbeing, and pharmacy strategy. 

Employers should work closely with their benefits advisors to understand emerging treatment options, assess potential cost impacts, and develop a long-term strategy that aligns employee health outcomes with business objectives. 

Organizations that proactively evaluate these trends today may be better positioned to manage future healthcare costs while supporting a healthier workforce. 

Frequently Asked Questions 

What is Foundayo? 
Foundayo is an FDA-approved oral GLP-1 medication developed by Eli Lilly for obesity treatment. It is taken once daily and helps regulate appetite. Learn more via the official FDA approval announcement. 

How is Foundayo different from Wegovy? 
Unlike the oral version of Wegovy, Foundayo does not require fasting or food restrictions before administration. As NPR reported, Foundayo's small-molecule formulation is easier for the body to absorb without dietary timing requirements, offering a practical advantage for patients with complex daily schedules. 

Will Foundayo increase employer healthcare costs? 
Potentially. Increased accessibility may drive greater employee demand for obesity treatment. Employers should evaluate utilization trends, coverage strategies, and long-term outcomes when assessing financial impact. Explore OneDigital's Pharmacy & PBM Consulting Services for expert guidance. 

Should employers cover oral GLP-1 medications? 
Coverage decisions depend on workforce needs, healthcare goals, plan design, budget considerations, and organizational priorities. Employers should work with trusted advisors to evaluate both clinical and financial implications. For a comprehensive framework, review OneDigital's GLP-1 Employer Coverage Decision Guide. 

Talk with a OneDigital Pharmacy Consultant 

Wondering how oral GLP-1 medications could impact your healthcare costs, pharmacy strategy, and workforce health goals? 

Connect with a OneDigital Pharmacy Consulting advisor to evaluate emerging trends, assess plan impacts, and build a sustainable approach to obesity management and healthcare cost containment. 

Ask us about our Smart Access program, a structured approach designed to help employers balance appropriate access to GLP-1 and specialty medications with clinical oversight, cost management, and member experience.